The IPO Buzz: Zenas BioPharma (ZBIO Proposed) Sets Terms & Launches $200 Million IPO
Zenas BioPharma (ZBIO Proposed), a Phase 2/Phase 3 clinical biotech focused on MS and other autoimmune diseases, disclosed the terms for its $199.9 million IPO and launched the deal early today – Friday, Sept. 6, 2024 – for pricing next week. The clinical biotech is offering 11.8 million shares at a price range of $16.00 to $18.00 to raise $199.9 million, if priced at the $17.00 mid-point of i..
Read more September 6, 2024IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Andretti Acquisition Corp. II | POLEU | 20.0 | $ 200.0 mil | 9/6/2024 Priced | S/O | S/O |
| Vine Hill Capital Investment Corp. | VCICU | 20.0 | $ 200.0 mil | 9/6/2024 Priced | S/O | S/O |
| Cuprina Holdings (Cayman) LTD | CUPR | 3.8 | $ 15.9 mil | 9/9/2024 Week of | S/O | S/O |
Last 100 IPOs - September 6, 2024
| Number of IPOs priced : | 100 |
| Number Up: | 47 |
| Number Down: | 51 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | 7.97% |
| Percentage Change for The Nasdaq Composite | -100.00% |
2024 IPO Scorecard - September 6, 2024
| Number of IPOs priced (Excluding 31 units) : | 109 |
| Number Up: | 50 |
| Number Down: | 57 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | 8.48% |
| The Nasdaq Composite Index YTD % Change | -100.00% |